ABSTRACT
Sulfonamides have been related to drug-induced acute angle closure of the eye, but scarce reports exist concerning furosemide. We describe the second case of acute chamber narrowing (ACN) during furosemide exposure. A 65-year-old man with a renal transplant presented with ACN, after 3 months of furosemide intake. Finally, the patient required a bilateral iridotomy and right lens replacement. ACN has been associated with drugs containing sulfonamide derivatives, but an evaluation with pharmacovigilance scales for adverse drug reaction (ADR)-standardised causality assessment has not been provided. We use this case to illustrate how medicines and an ADR should be evaluated and reported. The spreading of pharmacovigilance information on what should be a rare and unexpected condition related to a drug could mean that other reports emerge about ADR with this drug and regulatory agencies perform consequently, as happened with topiramate.
Subject(s)
Drug-Related Side Effects and Adverse Reactions , Pharmacovigilance , Adverse Drug Reaction Reporting Systems , Aged , Furosemide/adverse effects , Humans , Male , TopiramateABSTRACT
BACKGROUND: Primary nephrogenic diabetes insipidus (NDI) is a rare disorder and little is known about treatment practices and long-term outcome. METHODS: Paediatric and adult nephrologists contacted through European professional organizations entered data in an online form. RESULTS: Data were collected on 315 patients (22 countries, male 84%, adults 35%). Mutation testing had been performed in 270 (86%); pathogenic variants were identified in 258 (96%). The median (range) age at diagnosis was 0.6 (0.0-60) years and at last follow-up 14.0 (0.1-70) years. In adults, height was normal with a mean (standard deviation) score of -0.39 (±1.0), yet there was increased prevalence of obesity (body mass index >30 kg/m2; 41% versus 16% European average; P < 0.001). There was also increased prevalence of chronic kidney disease (CKD) Stage ≥2 in children (32%) and adults (48%). Evidence of flow uropathy was present in 38%. A higher proportion of children than adults (85% versus 54%; P < 0.001) received medications to reduce urine output. Patients ≥25 years were less likely to have a university degree than the European average (21% versus 35%; P = 0.003) but full-time employment was similar. Mental health problems, predominantly attention-deficit hyperactivity disorder (16%), were reported in 36% of patients. CONCLUSION: This large NDI cohort shows an overall favourable outcome with normal adult height and only mild to moderate CKD in most. Yet, while full-time employment was similar to the European average, educational achievement was lower, and more than half had urological and/or mental health problems.
ABSTRACT
Antecedentes: La biopsia del aloinjerto renal se realiza habitualmente con el paciente hospitalizado. Objetivo: Evaluar la seguridad y eficacia de un programa de biopsias ambulatorio en receptores de trasplante renal. Métodos: En diciembre de 2011 se inició un programa ambulatorio de biopsias en trasplante renal. Se contraindica la biopsia ambulatoria en los casos siguientes: 1) tratamiento anticoagulante, 2) trombocitopenia < 50 000/mm3, 3) índice de masa corporal > 35 kg/m2, 4) hipertensión arterial no controlada. Se compara la seguridad y eficacia de las biopsias realizadas bajo hospitalización en el período 2007-2011 (n = 124) con las biopsias ambulatorias realizadas durante el período 2011-2013 (n = 219) y las realizadas en este mismo período bajo hospitalización (n = 42). Resultados: Entre diciembre de 2011 y diciembre de 2013 se han indicado 230 biopsias desde la consulta externa y se han realizado 219 (95 %) en régimen ambulatorio. La incidencia de complicaciones mayores (necesidad de transfusión y/o embolización) ha sido de 0,8 % para el período 2007-2011 y de 2,4 % para las realizadas bajo hospitalización del período 2011-2013 (p = 0,475). No se observaron complicaciones mayores en el grupo de pacientes con biopsias realizadas de forma ambulatoria. La tasa de complicaciones menores (hematuria macroscópica, hematoma o fístula que no requirieron transfusión ni embolización) no ha sido distinta entre los grupos (3,2 %, 7,1 % y 2,7 %, respectivamente). La adecuación de la muestra obtenida según los criterios de Banff no ha sido distinta entre los grupos (p = 0,052). Conclusión: La realización ambulatoria de la biopsia de injerto renal es un procedimiento seguro y eficaz (AU)
Background: In many centers patients are hospitalised to perform a renal allograft biopsy. Aim: To evaluate the safety and efficacy of outpatient renal allograft biopsies. Methods: Since December 2011 we perform renal allograft biopsies as an outpatient procedure. Exclusion criteria for performing an outpatient biopsy included: 1.) anticoagulant treatment, 2.) thrombocytopenia <50,000/mm3, 3.) body mass index >35kg/m2 and 4.) uncontrolled hypertension. The number and severity of complications were compared with an historical cohort of 124 biopsies done between 2007 and 2011 when all patients were hospitalised for the procedure and with 42 patients biopsied during hospitalisation between 2011 and 2013. Results: Between 2011 and 2013, 210 (95%) out of 230 biopsies indicated in the outclinic were performed as an outpatient procedure (95%). The incidence of major complications (bleeding requiring blood transfusion and/or embolisation) was 0.8% between 2007 and 2011 and 2.4% in biopsies between 2011 and 2013 in hospitalised patients (p=0.475). No major complications were observed in the outpatient biopsy group. Minor complications (hematuria, hematoma or fistula not requiring transfusion or embolisation) were also not different between groups (3.2%, 7.1% and 2.7%; respectively). Sample size adequacy according to the Banff criteria was not different among groups (p=0.052). Conclusion: Ambulatory renal allograft biopsy is a safe and efficient procedure (AU)
Subject(s)
Humans , Biopsy/methods , Kidney Transplantation/methods , Patient Safety , Ambulatory Care , Preoperative Care/methods , Risk Factors , Biopsy , Postoperative Complications/epidemiology , Cohort Studies , Transplants/pathologyABSTRACT
BACKGROUND: In many centers patients are hospitalised to perform a renal allograft biopsy. AIM: To evaluate the safety and efficacy of outpatient renal allograft biopsies. METHODS: Since December 2011 we perform renal allograft biopsies as an outpatient procedure. Exclusion criteria for performing an outpatient biopsy included: 1.) anticoagulant treatment, 2.) thrombocytopenia <50,000/mm3, 3.) body mass index >35kg/m2 and 4.) uncontrolled hypertension. The number and severity of complications were compared with an historical cohort of 124 biopsies done between 2007 and 2011 when all patients were hospitalised for the procedure and with 42 patients biopsied during hospitalisation between 2011 and 2013. RESULTS: Between 2011 and 2013, 210 (95%) out of 230 biopsies indicated in the outclinic were performed as an outpatient procedure (95%). The incidence of major complications (bleeding requiring blood transfusion and/or embolisation) was 0.8% between 2007 and 2011 and 2.4% in biopsies between 2011 and 2013 in hospitalised patients (p=0.475). No major complications were observed in the outpatient biopsy group. Minor complications (hematuria, hematoma or fistula not requiring transfusion or embolisation) were also not different between groups (3.2%, 7.1% and 2.7%; respectively). Sample size adequacy according to the Banff criteria was not different among groups (p=0.052). CONCLUSION: Ambulatory renal allograft biopsy is a safe and efficient procedure.